Tyra Biosciences Reports $45.6 Million Net Loss in Q2 2026, Driven by Increased R&D Expenses

Tyra Biosciences, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending June 30, 2026. The company recorded a net loss of $45.6 million for the quarter, compared to a loss of $28.1 million in the same period last year, marking a 62% increase in losses year-over-year. For the first half of 2026, the net loss was $84.9 million, up from $56.2 million in the first half of 2025. The increase in losses is attributed primarily to heightened research and development expenses, which rose to $72.7 million for the six months ended June 30, 2026, compared to $49.3 million in the prior year.

Total operating expenses for the second quarter of 2026 reached $49 million, a 56% increase from $31.5 million in the same quarter of 2025. This increase was driven by a $14.9 million rise in research and development costs, largely due to ongoing clinical trials for the company's lead product candidate, oral dabogratinib. General and administrative expenses also increased, totaling $9.8 million for the quarter, up from $7.1 million in the previous year, reflecting higher personnel costs and stock-based compensation.

In terms of strategic developments, Tyra Biosciences has made notable progress in its clinical programs. The company is advancing oral dabogratinib through three Phase 2 trials targeting significant market opportunities in urothelial cancers and skeletal dysplasia. The ongoing trials, SURF303, SURF302, and BEACH301, are expected to yield initial results in 2027. Additionally, the company has expanded its employee base, with a total headcount increase contributing to the rise in operational costs.

As of June 30, 2026, Tyra Biosciences reported total assets of $383.4 million, a substantial increase from $282.6 million at the end of 2025. This growth was primarily driven by an increase in marketable securities, which rose to $280.1 million from $178.6 million. The company also successfully raised $147.9 million through an at-the-market offering program, which has bolstered its cash reserves. Tyra's cash, cash equivalents, and marketable securities totaled $353.9 million, which management believes will be sufficient to fund operations into the second half of 2028.

Looking ahead, Tyra Biosciences anticipates continued investment in its research and development activities, with expectations of increased operating expenses as it advances its clinical trials. The company has not generated any revenue to date and does not expect to do so until it successfully completes the development and regulatory approval of its product candidates. The management remains focused on securing additional funding through equity offerings or collaborations to support its ongoing operations and development efforts.